GLP-1-based meds are linked to fewer heart events in adults with obesity, autoimmune disease

Article excerpt

Adults with both obesity and autoimmune disease who took GLP-1 receptor agonist medications experienced fewer emergency department visits and serious cardiac events, including stroke, pulmonary embolism, and death, compared to untreated peers, according to research published in the Journal of the American Heart Association. The finding adds to growing evidence that these drugs, already known for weight loss and diabetes management, may offer cardiovascular protection in patients managing multiple conditions simultaneously.